Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Old Gemini [Member]	Roche	Series Seed Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member] Old Gemini [Member]	Common Stock [Member] Roche	Additional Paid-in Capital	Additional Paid-in Capital Old Gemini [Member]	Additional Paid-in Capital Roche	Retained Earnings [Member]
Balance at Dec. 31, 2021	$ (64,203)									$ 1,186			$ (65,389)
Balance (in shares) at Dec. 31, 2021				5,000,000	41,666,666	37,499,999
Balance at Dec. 31, 2021				$ 2,350	$ 49,762	$ 89,744
Balance (in Shares) at Dec. 31, 2021							909,418
Issuance of common stock upon exercise of stock options	219									219
Issuance of common stock upon exercise of stock options (in Shares)							53,224
Vesting of restricted common stock (in Shares)							8,254
Stock-based compensation expense	2,089									2,089
Issuance of common stock for cash in pre-closing financing	53,500									53,500
Issuance of common stock for cash in pre-closing financing (in Shares)							2,336,092
Conversion of preferred stock to common stock	141,856			$ (2,350)	$ (49,762)	$ (89,744)	$ 1			141,855
Conversion of preferred stock to common stock (in Shares)				(5,000,000)	(41,666,666)	(37,499,999)	9,224,653
Issuance of common stock		$ 91,391	$ 6,511					$ 1			$ 91,390	$ 6,511
Issuance of common stock shares								4,389,361	482,313
Reverse recapitalization transaction costs	(7,936)									(7,936)
Net Income (Loss)	(46,827)												(46,827)
Balance at Dec. 31, 2022	176,600						$ 2			288,814			(112,216)
Balance (in Shares) at Dec. 31, 2022							17,403,315
Issuance of common stock upon exercise of stock options	$ 2,763									2,763
Issuance of common stock upon exercise of stock options (in Shares)	254,432						254,432
Vesting of restricted common stock (in Shares)							1,916
Stock-based compensation expense	$ 5,530									5,530
Sale of common stock in registered direct offering	34,148									34,148
Sale of common stock in registered direct offering, (in shares)							1,488,166
Sale of pre-funded warrants in registered direct offering	28,206									28,206
Sale of common stock in at-the-market offerings	26,422									26,422
Sale of common stock in at-the-market offerings, (in shares)							967,264
Sale of common stock in In follow on public offering	138,508									138,508
Sale of common stock in follow on public offering, (in shares)							3,015,919
Sale of pre-funded warrants in follow-on public offering	9,373									9,373
Shares issued upon exercise of warrants							1,229,221
Net Income (Loss)	(76,429)												(76,429)
Balance at Dec. 31, 2023	$ 345,121						$ 2			$ 533,764			$ (188,645)
Balance (in Shares) at Dec. 31, 2023							24,360,233